Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $34 to $33.
Evercore ISI Group analyst Gavin Clark-Gartner maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $34 to $33.